On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.

Journal: Artificial intelligence in medicine
PMID: 31607342

Abstract

OBJECTIVES: We develop a fuzzy evaluation model that provides managers at different responsibility levels in pharmaceutical laboratories with a rich picture of their innovation risk as well as that of competitors. This would help them take better strategic decisions around the management of their present and future portfolio of clinical trials in an uncertain environment. Through three structured fuzzy inference systems (FISs), the model evaluates the overall innovation risk of the laboratories by capturing the financial and pipeline sides of the risk.

Authors

  • Javier Puente
    Department of Business Administration, University of Oviedo, Spain. Electronic address: jpuente@uniovi.es.
  • Fernando Gascon
    Department of Business Administration, University of Oviedo, Spain. Electronic address: fgascon@uniovi.es.
  • Borja Ponte
    Department for People and Organisations, The Open University, UK. Electronic address: borja.ponte-blanco@open.ac.uk.
  • David de la Fuente
    Department of Business Administration, University of Oviedo, Spain. Electronic address: david@uniovi.es.

Keywords

External Resources

Popular Topics
Recent Journals